No bills from pharma, health sectors likely to come up for discussion during Winter Session
No bills from the pharma and health sectors, including the controversial National Biotechnology Regulatory Authority (NBRA) bill, may be introduced during the Winter Session.
No bills from the pharma and health sectors, including the controversial National Biotechnology Regulatory Authority (NBRA) bill, may be introduced during the Winter Session commencing on November 22 since over 100 bills already tabled in the Parliament are waiting for the look by the lawmakers.
The session which will go on till December 20 will take up the pending bills, including some crucial ones, on a priority basis instead of listing fresh bills for consideration, provided that the political turmoil does not waste the time of the Houses, sources said.
One of the prominent bills related to the pharma and health sector was the NBRA bill which was slated to be tabled on the last day of the monsoon session. However, it was stalled even the Minister concerned was about to present the bill, following stiff opposition from different parties including the ruling sections.
Though the provisional calendar was yet to be announced for the winter session, it is learnt that the Government had decided to push some of the pending bills. As many as 102 bills are pending for consideration by either House after the several sessions were disrupted continuously in the past. These pending bills include ones on land acquisition, Lokpal, whistle-blowers, money-laundering, companies, banking and forward contracts regulation.
The government had promised to address concerns of the MPs before tabling the NBRA bill, virtually pushing it back to the cold storage. The apprehensions by the Members about genetically modified crops and other products forced the government to withdraw the bill at the last minute.
Apart from the NBRA bill, a number of bills from the sector are also pending for presentation. Major Bills included HIV/AIDS bill, ethical guidelines for biomedical research on human subjects bill, Central Drug Authority (CDA) bill and ART bill.
The HIV/AIDS bill that aims to end discrimination to the HIV patients and ensuring access to treatment to them is mired in controversy and is presently stuck in the union law ministry. The tabling of ethical guidelines for biomedical research on human subjects bill in this session is also difficult as the Indian Council of Medical Research (ICMR) is reviewing the bill to make the punishment part of the bill more severe as a deterrent.
Related News
-
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Women in Pharma: Diversi‘tea’ at CPHI North America
CPHI North America will unite the pharmaceutical supply chain in Philadelphia from May 7–9, 2024 for 3 days of innovation and connections. As part of the content Agenda, our Diversity Track will bring the industry together to discuss the imperati... -
News More to celebrate at the CPHI Milan Pharma Awards 2024
The CPHI Milan Pharma Awards, which are now open for nominations until 18 May 2024, celebrate the innovators making a difference. This year, two new categories have been added to further honour the contributions of a diverse range of pharma professiona... -
News On Track at CPHI NA 2024: Sustainable Futures with Thermo Fisher Scientific
On the 7-9 May 2024 in Philadelphia, CPHI NA will be presenting an unmissable agenda, filled with content across 4 main tracks. In the following interview the Sustainable Futures Track sponsor, Thermo Fisher Scientific gives an overview of what to expe... -
News LEAP-ing into the future of pharma – the CPHI Middle East Vision
On March 6, 2024, the CPHI team hosted the Future of Pharma Forum at LEAP 2024, Saudi Arabia’s premier destination for tech leaders and innovators to meet and collaborate. -
News CPHI Middle East 2024 – What do we have to look forward to?
We’re bringing CPHI to the Middle East in December 2024. CPHI brings together the pharma community from all over the world, creating a platform for education, collaboration, and progress. -
News CPHI Pharma Awards 2023 – Packaging & Machinery Winner: Gasporox
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October 2023. In this series of interviews, we speak to the people and teams behind the award-winning projects, concepts, and techno... -
News Unpacking what we learnt: Key Pharmapack takeaways with L.E.K. Consulting
After another successful Pharmapack show, we sat down with Karin von Kienlin, Senior Partner at L.E.K. Consulting, to discuss the biggest takeaways and surprises from 2 days of intense discussion and collaboration.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance